Related Experiment Video
Updated: Jan 7, 2026
07:50
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
16.4K
Clinical Manifestations
Gabriela Tomé Oliveira Engelmann1,2,3, Giovanna Correia Pereira Moro1,2,4, Ivonne Carolina Bolaños Burgos5
1Older Adult's Psychiatry and Psychology Extension Program (PROEPSI), School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
Summary
Higher phosphorylated tau protein (p-Tau 181) levels correlate with poorer performance on memory and cognitive assessments in older adults. This finding aids in understanding Alzheimer's disease progression and risk factors.
Area of Science:
- Neuroscience
- Biomarker Research
- Gerontology
Background:
- Understanding Alzheimer's disease (AD) biomarkers and cognitive decline is crucial for identifying risk factors for dementia.
- The Dementia Rating Scale (DRS) assesses cognitive function, while cerebrospinal fluid (CSF) biomarkers like Aβ42 and p-Tau 181 indicate AD pathology.
Purpose of the Study:
- To investigate the association between CSF Aβ42, p-Tau 181 levels, and performance on the DRS in older adults.
- To determine if these biomarkers can predict cognitive decline and conversion to Alzheimer's Disease Dementia (ADD).
Main Methods:
- Sixty-four participants (Cognitively Unimpaired, Mild Cognitive Impairment, ADD) were analyzed.
- CSF Aβ42 and p-Tau 181 levels were measured using Luminex xMAP.
- Spearman correlation and adjusted linear regression analyses were performed to assess relationships between biomarkers and DRS performance.
Main Results:
- Elevated CSF p-Tau 181 levels significantly correlated with worse performance on DRS Memory and total scores (DRST).
- No significant correlation was observed between CSF Aβ42 and DRS performance.
- The p-Tau 181/Aβ42 ratio also showed a significant negative correlation with Memory and DRST scores.
Conclusions:
- Higher p-Tau 181 levels are associated with poorer cognitive function, particularly in memory, as measured by the DRS.
- This association persists even after adjusting for sociodemographic factors, highlighting p-Tau 181's potential as a predictive biomarker for cognitive decline in Alzheimer's disease.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
01:30Coronary Artery Disease III: Clinical Manifestations
299
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
299
01:25Endocarditis II: Clinical Features of Infective Endocarditis
364
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
364
01:26Heart Failure III: Clinical Manifestations
436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
652
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
652
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437